NCI_60_Thioguanine: Drug Activity Patterns in 60 Human Tumor Cell Lines

60 cell lines from the NCI-60 panel, established by the National Cancer Institute's Developmental Therapeutics Program, are used to screen chemical compound toxicity. The dataset appears to be a pharmacogenomic study investigating patterns of drug activity, specifically for the drug Thioguanine, across cancers of colorectal, renal, ovarian, breast, prostate, lung, central nervous system, leukemia, and melanoma origin. It is authored by Gergely Szakacs and licensed by Elsevier.

Use Cases

• Predict drug sensitivity or resistance based on cell line origin and features mentioned in the description.
• Identify biomarkers associated with Thioguanine response across diverse cancer types.
• Screen for potential toxicity of chemical compounds using the established NCI-60 panel as a reference.
• Cluster cancer cell lines by drug activity patterns to discover novel pharmacological subgroups.

Strengths

• Data is derived from the well-established NCI-60 panel, a standard resource for anticancer drug screening.
• Covers cell lines from 9 distinct cancer types, including 8 breast, 9 lung, and 8 melanoma lines, providing diversity.
• Focuses on a specific drug (Thioguanine), enabling targeted pharmacogenomic analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count and dataset size are unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

National Cancer Institute (NCI) Developmental Therapeutics Program

Collection Method

Screening of chemical compound repositories for toxicity in established cancer cell lines.

Time Range

unknown

Freshness

unknown

Geography

unknown